Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
4.560
0.00 (0.00%)
At close: Apr 28, 2026, 4:00 PM EDT
4.600
+0.040 (0.88%)
After-hours: Apr 28, 2026, 7:56 PM EDT
Nuvation Bio Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Nuvation Bio stock have an average target of 11.38, with a low estimate of 7.00 and a high estimate of 17. The average target predicts an increase of 149.56% from the current stock price of 4.56.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nuvation Bio stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 9 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +141.23% | Apr 16, 2026 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +141.23% | Apr 2, 2026 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +141.23% | Mar 27, 2026 |
| UBS | UBS | Hold Maintains $10 → $7 | Hold | Maintains | $10 → $7 | +53.51% | Mar 3, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $12 → $13 | Buy | Maintains | $12 → $13 | +185.09% | Mar 3, 2026 |
Financial Forecast
Revenue This Year
191.11M
from 62.90M
Increased by 203.82%
Revenue Next Year
302.29M
from 191.11M
Increased by 58.18%
EPS This Year
-0.49
from -0.60
EPS Next Year
-0.27
from -0.49
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 233.6M | 411.2M | ||||||
| Avg | 191.1M | 302.3M | ||||||
| Low | 139.9M | 214.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 271.4% | 115.2% | ||||||
| Avg | 203.8% | 58.2% | ||||||
| Low | 122.4% | 12.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.38 | - | ||||||
| Avg | -0.49 | -0.27 | ||||||
| Low | -0.90 | -0.58 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.